SCHEDULE 13G/A: RTW Investments and Dr. Roderick Wong Disclose 2.5% Stake in ESSA Pharma Inc.
Beneficial Ownership Disclosure
RTW Investments, LP and its Managing Partner, Dr. Roderick Wong, have jointly disclosed a beneficial ownership of 2.5% of ESSA Pharma Inc.'s common shares as of December 31, 2024.
Summary
- RTW Investments, LP and Roderick Wong, M.D. (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in ESSA Pharma Inc.
- As of December 31, 2024, the Reporting Persons collectively beneficially own 1,113,002 Common Shares of ESSA Pharma Inc.
- This ownership represents 2.5% of the total outstanding Common Shares, calculated based on 44,388,550 shares outstanding as of December 16, 2024, as reported in the Company's Annual Report on Form 10-K.
- Both RTW Investments and Dr. Wong share voting and dispositive power over all 1,113,002 beneficially owned shares.
- The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing disclosing beneficial ownership and does not contain information that would significantly alter the perceived sentiment towards the issuer's operational or financial performance. It is a neutral, factual disclosure.
Positives
- RTW Investments, a notable investment adviser, and its Managing Partner, Dr. Roderick Wong, maintain a significant stake in ESSA Pharma Inc., indicating continued interest from institutional investors.
Negatives
- No specific negative information regarding ESSA Pharma Inc.'s operations or financial health is disclosed in this ownership filing.
Risks
- The filing includes a standard disclaimer that it should not be construed as an admission that any Reporting Person is a beneficial owner for the purposes of Section 13 of the Securities Exchange Act of 1934.
Future Outlook
The document is a regulatory filing disclosing beneficial ownership and does not contain any forward-looking statements or guidance regarding the issuer's future performance or outlook.
Industry Context
This filing is a standard disclosure of an institutional investor's stake in a publicly traded company within the biotechnology or pharmaceutical sector. It does not provide specific insights into broader industry trends or competitive landscape beyond the fact of the investment.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, which can be a signal of investor confidence or interest.
Key Dates
| Date | Description |
|---|---|
| 12/16/2024 | Date as of which 44,388,550 shares outstanding were reported in ESSA Pharma Inc.'s Annual Report on Form 10-K. |
| 12/31/2024 | Date of event which required the filing of this statement (beneficial ownership calculation date). |
| 02/14/2025 | Date the Schedule 13G Amendment No. 2 was signed by the Reporting Persons. |
Keywords
ESSA Pharma Inc., RTW Investments, Roderick Wong, Schedule 13G, beneficial ownership, common shares, investment, biotechnology, pharmaceutical
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.